Lets be fair loh...the share call on investing in gloves companies is hold call.....no longer a buy call mah...!!
Yes the gloves profit will still increase in 1 or 2 more qtr but no more loh....!!
This bcos the following mah;
1. Excess capacities due to existing players expansion and many more new players.
2. The consumers medical instituite had cautiously over ordered & over stocked as a precaution now has slowly unwinding their inventories
3. The demand had reduced due to less pressing number of covid case and less fear now.
4. Most importantly the average selling price of gloves will be starting to fall in the next 1 to 2 qtr due excess competition coming in loh..!!
Just hang with your gloves while waiting for good gloves profit flowing but be ready lari kuat kuat bcos the profits cannot sustained high in longer term loh...!!
NeutralInvestor Reading the notes to the Q4'20 report, there are one-off provisions and expenses recognised in this Q4 of RM21.64m. Adding that back to the PBT of RM59.5m, Q4 PBT wld have been RM81.1M, a big jump from Q3'20 PBT of RM49.7m. This has also not yet accounted for the roughly 2-3 weeks of shutdown and loss of production/sales in Q4'20 due to the Covid infection at the plant.
As such, and with ASPs continually rising, the coming Q1'21 results should show a very big jump from Q4'20 numbers and this cld be announced as early as end Apr'21.
Prospects (as per the 4th Quarter Ended 31 December 2020 )
We are now running 30lines with an annual capacity of 4.86billion pieces of gloves. By mid ofJune2021, weshall complete installation of10lines and another 8lines by the end of 2021, with an addition of 9lines in planning stage to be completed by end of 2022.As a result,the Group will have 57production lines with an annual capacity of 10.5 billion piecesof medical and surgical gloves byend2022. The Group has also put in place to increase surgical gloves packing facilities from 72million pairs to 288million pairs annuallyby end 2021.Barring any unforeseen circumstances, we are confident we will be able to commission and run all the production as planned.
Careplus 3Q20 PAT RM 42.9 Mil included the one-off gain of RM 15.4 Mil from the disposal of 50% equity interest in Careplus for the joint venture with Ansell in the last year second quarter.
So its actual 3Q20 PAT from just glove revenue was RM 42.9 - RM 15.4 = RM 27.5 Mil.
4Q20 PAT from just glove revenue is RM 42.2 Mil.
Now do the math. An increase of PAT RM 14.7 Mil in just one quarter. A whooping +53% increase in PAT from glove revenue.
So very clear indication that Average Selling Price has indeed gone up significantly. The numbers do not lie. These are the facts. The glove peak is yet to come.
LOL Is this the same foker that was telling everyone in Lotte Chem forum that it is fully valued at RM1.6 back in Apr 20 with his Graham methodology. Maybe you better go back and study so you can at least spell your name correctly
Glove companies won’t die, just leave the forum if you are not interested. Foker- what are you trying to prove other than you’re a dumbass self promoting Ass hole full of hot air and arrogance?
No Foker, you need to stop your nonsense. You believe what you want, but karma will get you. Gloating over someone’s financial loss will bring you a load of bad luck. You’re not doing this to help anyone, only to promote your own self importance. And make people feel worse. No need to be an asshole.
I’m holding very happily to what I have. But I am leaving this toxic forum.
Take care all, don’t lose hope, take it easy and just diversify when you can.
Noobee88 : He is a kid that limited financial knowledge but wants to be a sifu. Just ignore him coz he is dying for people attention. Yes gloating over peoples loss should not be encouraged but thats his karma and probably why he is suffering so much
You should read LCT forum back in Apr 20 see what this 'genius' said.
Let us not celebrate other peoples losses; just put our case across and move on rather than ridicule. Then the enviornment would not be so toxic. Shorties need to get a life
There has been a 45% increase in global demand for nitrile disposable gloves since the start of COVID-19. Put that into figures, the supply and demand deficit equates to a shortfall of 214 billion disposable gloves - demand has exploded while the supply is only growing incrementally.
US-based Allied Market Research estimates that the global disposable gloves market amounted to $6.8 billion in 2019, and is expected to nearly triple to $18.8 billion by 2027.
This is leading to glove manufacturers posting record profits, attributed to the increased production, a higher volume of gloves sold and significantly higher average selling prices compared with 2019. Net profits as high as a sevenfold increase are now being reported.
2. PRODUCTION COSTS AND CAPACITY
As glove manufacturers produce at their maximum output, the increased glove demand continues to far exceed global supply availability.
The lack of workers in glove manufacturing, due to health and social restrictions of the pandemic, is resulting in increased production costs. Factories must implement Covid testing to avoid the spread of the virus in their facilities, otherwise lockdown measures occur, as has happened to one of the world’s largest glove manufacturers, affecting thousands of workers.
There are also reports of nitrile glove capacity constrained by the shortage of glove moulds, which are essential for production.
3. RAW MATERIALS
The worldwide shortage of nitrile gloves is predicted to continue for more than a year into the first half of 2022 due to a lack of raw materials.
Factories that supply the raw materials are adding new capacity based on the previous year’s demand - insufficient for current demand levels. Building new factories to handle the current demand of nitrile rubber can take upwards of 18 months to be operational.
"The shortage of raw material for our nitrile gloves and the disruption to the supply or production of other material such as packaging materials due to the global lockdown, has caused an increase in the production cost," according to the world's biggest producer of rubber gloves.
4. THIRD-PARTY DEALERS AND HEDGE FUND INVESTMENTS
Social media is awash with third-party dealers offering gloves at exorbitant prices to those desperate enough to purchase from them, in order for their business to continue to operate. Some factories are offloading rejected quality stock they are unable to sell directly to hospitals and governments without legal risks. That is, rejected stock off the production line, offloaded through freight forwarders and third-party brokers without export paperwork which is legally required.
Additionally, investment firms are financing glove purchasing deals in return for large profit share, which in turn is driving total glove cost.
The culmination of these factors are the reason nitrile glove users have seen a dramatic increase in cost throughout 2020. With prices likely to continue increasing for the foreseeable future, purchasing gloves, especially during a pandemic, does come with quality and safety issues for users, particularly in the medical and food industries.
The preliminary scientific results of the Pfizer-BioNTech Covid-19 vaccination programme in Israel, although not peer reviewed yet, look promising.
In the report “Estimating real-world Covid-19 vaccine effectiveness in Israel”, published in medRxiv dated Feb 11, author Dvir Aran said the vaccine has a high effectiveness of 66% to 85% in reducing SARS-CoV-2 positive cases, and over 90% in reducing severe cases which can result in hospitalisation and death.
Daily positive cases and hospitalisation data were taken from the Israeli health ministry’s Covid-19 public database for the study.
Between Dec 20 and Jan 31, as many as 3,082,190 individuals in Israel were given the first dose of the vaccine and 1,789,836 have already had their second dose, according to the report.
Of those vaccinated, 31,810 tested positive for SARS-CoV2, and 1,525 were hospitalised with severe or critical conditions or died.
That was after the first dose and at the beginning of a third wave, which saw positive cases and hospitalisations more than double. A strict lockdown was imposed on Jan 8.
There were again doubts about the vaccines but the number of cases had fallen by 66%, seven days after the second dose.
Israel, in turn, would serve as a “global model state for the rapid vaccination of an entire country” and will send Pfizer anonymised medical information about the effects of the vaccine on the population.
The results from the data, once reviewed by the medical community, may prove useful ahead of Israel’s elections this March.
While the data looks promising, there are still a couple of questions that warrant confirmation.
The preliminary report did not differentiate between the impact resulting from vaccination and that of the lockdown. To what extent did the lockdown affect the reduction in the number of cases and severity of cases? Or was it all the work of the vaccine?
According to an analysis by the journal Nature, separating the population-level effects of vaccines from the impacts of other public-health interventions, such as social distancing and lockdowns, will be tricky and requires a lot more data.
The analysis also noted that Covid-19 vaccines would not have an impact on viral spread so soon as herd immunity will have to be reached first.
The results from the data, once reviewed by the medical community, may prove useful ahead of Israel’s elections this March.
While the data looks promising, there are still a couple of questions that warrant confirmation.
The preliminary report did not differentiate between the impact resulting from vaccination and that of the lockdown. To what extent did the lockdown affect the reduction in the number of cases and severity of cases? Or was it all the work of the vaccine?
According to an analysis by the journal Nature, separating the population-level effects of vaccines from the impacts of other public-health interventions, such as social distancing and lockdowns, will be tricky and requires a lot more data.
Could it be political gimmick due to Israel election on March ?? D.Trump style b4 election ?
Yet yo know after March
While the data looks promising, there are still a couple of questions that warrant confirmation.
The preliminary report did not differentiate between the impact resulting from vaccination and that of the lockdown. To what extent did the lockdown affect the reduction in the number of cases and severity of cases? Or was it all the work of the vaccine?
Spain: Second Pfizer Shots Halted After 46 Nursing Home Residents Die After The First ShotHAFHAFFebruary 18, 2021
CORONAVIRUSHEALTHCARENEWSVACCINESSpain: Second Pfizer Shots Halted After 46 Nursing Home Residents Die After The First ShotHAFHAFFebruary 18, 2021 Sponsored by RevcontentTrending Now LOS BARRIOS, SPAIN — The Nuestra Señora del Rosario (Our Lady of the Rosary) nursing home is reeling due to mass deaths after mRNA inoculations.
All residents and workers at the facility received the first dose of Pfizer mRNA in early January, according to Spain mainstream media outlet ABC de Sevilla.
Most residents became extremely ill shortly after the shots. It is believed many came down with COVID-19, despite being “vaccinated against it.”
The Andalusian Health Service reported that at least 46 residents have died since January. For perspective, Our Lady has a maximum capacity of 145 residents.
The Junta de Andalucía (regional government) intervened in early February to curtail the death count. But people continued dying. Spain’s Ministry of Health is now in charge of mitigation.
The Ministry said in a statement:
“In view of the imminent risk to public health, and in particular for the [residents] and workers of this center, as the current protocol for disinfection and isolation of positive cases cannot be guaranteed.”
The situation remains dire, as at least 28 residents and 12 staff members were COVID-19 positive last week. Health officials halted all further mRNA shots as a result.
The Federation of Public Services criticized Our Lady for not taking action sooner.
The workers’ union said the response was inadequate after eight people died by January 18. The death count grew to 30 by January 28.
Spain is continually in the news related to mRNA shots. Health Minister Salvador Illa said in December that his agency is keeping a database of all citizens who refuse the mRNA. He said the list will be shared with all EU members.
A healthcare worker in Spain also recently reported that several mRNA recipients have been admitted to Hospitals in the Region of Murcia for encephalitis.
Source: TheCovidBlog.com / Reference: Sevilla.abc.es 22/02/2021 12:58 AM
Stock [CAREPLS]: CAREPLUS GROUP BHD Announcement Date 19-Feb-2021 Financial Year 31-Dec-2020 Subject Special Dividend Type Dividend - Normal or Special Description Special Dividend of 2.0 sen per ordinary share Amount RM 0.0200 Ex Date 05-Mar-2021 Entitlement Date 08-Mar-2021 Payment Date 24-Mar-2021
Judgement done, below RM2. Buy high, reload high, what a sad, dude gg
Posted by VenFx > Feb 22, 2021 9:01 AM | Report Abuse
Careplus s f.v. at currently set if results demand at least $2.81 per share. It shud demand higher, by assuming no plus or minus from careplus s latest q4 results of which u shall get a $0.305 eps . To look furthur, let's read the below;
Everyone who does a F.A. study knowing careplus will gear up for another net increasing for their production upon it's additional 10 lines completed by mid 2021.
Thus, its eps will be able to score at $0.375 eps in its fy2022.
So, how undervalued is careplus at currently $2.03 ? Pls do your own judgement.
Careplus's f.v. at currently set of results demand at least $2.81 per share. It shud demand higher, by assuming no plus or minus from careplus s latest q4 results of which u shall get a $0.305 eps . To look furthur, let's read the below;
Everyone who does a F.A. study knowing careplus will gear up for another incrent by 46% of its production upon it's additional 10 lines completed by mid 2021.
Thus, its eps will be able to score at $0.375 eps in its fy2022.
So, how undervalued is careplus at currently $2.03 ? Pls do your own judgement.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
stockraider
31,556 posts
Posted by stockraider > 2021-02-20 16:44 | Report Abuse
Lets be fair loh...the share call on investing in gloves companies is hold call.....no longer a buy call mah...!!
Yes the gloves profit will still increase in 1 or 2 more qtr but no more loh....!!
This bcos the following mah;
1. Excess capacities due to existing players expansion and many more new players.
2. The consumers medical instituite had cautiously over ordered & over stocked as a precaution now has slowly unwinding their inventories
3. The demand had reduced due to less pressing number of covid case and less fear now.
4. Most importantly the average selling price of gloves will be starting to fall in the next 1 to 2 qtr due excess competition coming in loh..!!
Just hang with your gloves while waiting for good gloves profit flowing but be ready lari kuat kuat bcos the profits cannot sustained high in longer term loh...!!